Comparative therapeutic effect of moxidectin, doramectin and ivermectin on psoroptes mites infestation in buffalo (Bubalus bubalis).
The aim of the present study was to carry out comparative therapeutic effect of moxidectin pour on, doramectin and ivermectin on psoroptes infestation in buffalo. A total of 318 buffalo in 77 small scale herds suspected to have mange mites were examined clinically and parasitologically. Fifty-three (16.66%) buffalo in 25 herds were recorded to be infested; 51 (16.35%) with psoroptic mites, and two (0.31%) with chorioptic mites. Buffalo with psoroptic mites were randomly allocated into three groups (17 buffalo each). First group was treated with moxidectin pour on at a dose rate of 0.5 mg kg(-1). The second group received doramectin (200 microg kg(-1) twice subcutaneously, 14 days apart). The third group received ivermectin (200 microg kg(-1) twice subcutaneously, 14 days apart). Adjunct to each drug, deltamethrin was applied to the surrounding environment twice at a two week interval. Treatment outcomes of 51 buffalo with psoroptic mites showed that moxidectin pour on and doramectin had a significant higher effect on mite count reduction (MANOVA, P < 0.01; Walks' Lambda, P < 0.01) and clinical sum scores (MANOVA, P < 0.05; Walks' Lambda, P < 0.05) compared with injectible ivermectin. On clinical level, the number of clinically recovered buffalo in moxidectin and doramectin treated groups was significantly (P < 0.05) higher than that of ivermectin treated group. The result of the present study indicated that psoroptic mites are the main cause of mange in buffalo in Lower Egypt. This is the first report that describes the effect of moxidectin in buffalo. Moxidectin is a good alternative and easily applied drug for treatment of psoroptes infestation in buffalo.
Department of Internal Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Mansoura University, Mansoura, 35516, Egypt.
Sabry A
SA
el-Khodery
Mitsu
M
Ishii
Salama A
SA
Osman
Magdy H
MH
Al-Gaabary
D000704:Analysis of Variance; D000818:Animals; D000977:Antiparasitic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002020:Buffaloes; D004534:Egypt; D007559:Ivermectin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D018942:Macrolides / Q000494:pharmacology / Q000627:therapeutic use; D008924:Mite Infestations / Q000188:drug therapy* / Q000662:veterinary*; D009570:Nitriles; D040042:Psoroptidae / Q000187:drug effects*; D011722:Pyrethrins
D000977:Antiparasitic Agents; D018942:Macrolides; D009570:Nitriles; D011722:Pyrethrins; C017180:decamethrin; D007559:Ivermectin; C084101:doramectin; C027837:moxidectin